ALBANY, New York, November 28, 2017 /PRNewswire/ -- Majorly, chronic myelogenous leukemia (CML) occurs in adults, however, it sometimes occurs in children as well. However, targeted drugs called Tyrosine-Kinase Inhibitors (TKIs) have been effective in providing long-term survival...
from PR Newswire: //www.prnewswire.co.uk/news-releases/chronic-myelogenous-leukemia-treatment-market-value-to-reach-us-85508-million-by-the-end-of-2026-660508343.html
No comments:
Post a Comment